Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals

Clinical Microbiology and Infection

Volumn 13, Issue 3, 2007, Pages 269-276

  Mackenzie, F M ^a   Bruce, J ^b   Struelens, M J ^c   Goossens, H ^d,e   Mollison, J ^b   Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ERASME HOSPITAL   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antimicrobial use; ARPAC; European hospitals; Infection control policies; MRSA prevalence; Nosocomial infection

Indexed keywords

ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; MACROLIDE; METICILLIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; CONFIDENCE INTERVAL; DRUG USE; EUROPE; GEOGRAPHIC DISTRIBUTION; HAND WASHING; HEALTH CARE POLICY; HOSPITAL; HUMAN; INFECTION CONTROL; LINEAR REGRESSION ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 34247274240     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01592.x     Document Type: Article

References (21)

1. Perencevich EN, Hartley DM. Of models and methods: Our analytic armamentarium applied to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2005; 26: 594-597.
2. Richet H, Benbachir M, Brown DE et al. Are there regional variations in the diagnosis, surveillance, and control of MRSA? Infect Control Hosp Epidemiol 2003; 24: 334-341.
3. Ward MM, Diekema DJ, Yankey JW et al. Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in US hospitals. Infect Control Hosp Epidemiol 2005; 26: 31-38.
4. Harbarth S. Control of nosocomial methicillin-resistant Staphylococcus aureus: Where shall we send our hospital director next time? Infect Control Hosp Epidemiol 2005; 24: 314-316.
5. Bonten MJM, Austin DJ, Lipstich M. Understanding the spread of antibiotic resistant pathogens in hospitals: Mathematical models as tools for control. Clin Infect Dis 2001; 33: 1739-1746.
6. National Committee for Clinical Laboratory Standards. Analysis and presentation of cumulative antimicrobial susceptibility test data. Approved guideline, document M39-A2. Wayne, PA: NCCLS, 2005.
7. Monnet DL. ABC Calc-antibiotic consumption calculator (Microsoft Excel application), v. 2. 0. Copenhagen: Statens Serum Institut, 2004.
8. Anonymous. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs). Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2004.
9. Pittet D, Mourouga P, Perneger TV. Compliance with handwashing in a teaching hospital. Infection Control Program. Ann Intern Med 1999; 130: 126-130.
10. Vos MC, Verbrugh HA. MRSA: We can overcome, but who will lead the battle? Infect Control Hosp Epidemiol 2005; 26: 117-120.
11. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis WR. The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol 1996; 17: 150-158.
12. White RL. How do measurements of antibiotic consumption relate to antibiotic resistance? In: Gould IM, van der Meer JWM, eds, Antibiotic policies; theory and practice. New York: Kluwer, 2005; 75-103.
13. Carmeli Y, Castro J, Eliopoulos GM, Samore MH. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Antimicrob Agents Chemother 2001; 45: 275-279.
14. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: Effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001; 127: 443-450.
15. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31: 1380-1385.
16. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-1422.
17. Monnet DL, MacKenzie FM, López-Lozano J et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-1440.
18. Muller AA, Mauny F, Bertin M et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003; 36: 971-978.
19. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20: 31-36.
20. Landman D, Chockalingam M, Quale J. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28: 1062-1066.
21. European Antimicrobial Resistance Surveillance System. EARSS annual report 2001. Bilthoven: National Institute for Public Health and the Environment, 2001.